Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

PR77992

SYDNEY, March 25, 2019 /PRNewswire=KYODO JBN/ --

Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA,

NASDAQ: KZIA) has been selected to present data from the Phase I study of

Cantrixil in ovarian cancer at the American Association for Cancer Research

(AACR) 2019 Annual Meeting.

Logo - https://photos.prnasia.com/prnh/20171120/1996749-1LOGO

AACR's Annual Meeting is one of the top-tier academic conferences worldwide and

brings together around 20,000 representatives from academia, industry,

government and advocacy organisations from across the globe. The meeting is

being held from 29 March to 3 April at the Georgia World Congress Center in

Atlanta, Georgia, USA.

Clinical Program Director, Daniel Berg will be presenting on Kazia's Cantrixil

Phase I in ovarian cancer at the event on 1 April 2019. Mr Berg will present

data from Part A of the study -- the dose escalation component -- which

completed recruitment in October 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with

activity against cancer stem cells and is being developed to treat ovarian

cancer. It was developed in Australia and initial preclinical studies were

conducted at Yale University. Cantrixil was granted orphan designation for

ovarian cancer by the US FDA in April 2015.

The abstract presentation is entitled: Phase I Study of Intraperitoneal

TRX-E-002-1 in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian

Tube Cancer or Primary Peritoneal Cancer: Results of Dose-Escalation Phase.

The abstract has been authored by the trial's Principal Investigators (PIs) -

led by the two primary PIs in Australia and the US: Associate Professor

Jermaine Coward at the ICON Cancer Care in Brisbane, Queensland and Dr Don

Dizon at the Lifespan Cancer Institute at Rhode Island Hospital. The trial is

being conducted across six sites in the US and Australia as follows:

Country      State        Site                      Principal Investigator

US      Rhode Island    Lifespan Cancer Institute,   Dr. Don Dizon

                                 Providence

US      Oklahoma      Stephenson Cancer Center,    Assoc. Prof. Kathleen Moore

                              Oklahoma City

US      Texas      Mary Crowley Cancer          Dr. Minal Barve

                        Research Centre, Dallas

Australia    Queensland      ICON Cancer Care, Brisbane   Assoc. Prof. Jermaine

                                                                                  Coward

Australia    New South Wales Westmead Hospital, Sydney    Prof. Paul Harnett

Australia    South Australia Flinders Medical Centre,     Dr. Ganessan

                                       Adelaide                            Kichenadasse

"The key objective with Part A of the Phase I study was to assess the safety of

the drug and find the right dose level to take the study to the next stage. We

are delighted to be presenting our data at the AACR meeting and we look forward

to discussing our findings with clinicians and potential partners," said

Cantrixil Program Director Daniel Berg.

The presentation session details are as follows:

Session Title: Phase I Clinical Trials: Part 3

Date and Time: Monday April 1, 2019 1:00 PM - 5:00 PM

Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16

Poster Board Number: 15

Permanent Abstract Number: CT091

Interested parties are encouraged to attend and can add the session to their

itinerary here: https://www.abstractsonline.com/pp8/#!/6812/session/1315

Meanwhile, the link to the abstract is here:

https://www.abstractsonline.com/pp8/#!/6812/presentation/9899

The content of the abstract and presentation is embargoed until the start of

the conference when it will be available through the above link and on the

Kazia website.

***ENDS***

For more information on Kazia Therapeutics or Cantrixil, please visit:

www.kaziatherapeutics.com

SOURCE  Kazia Therapeutics Ltd